Cost-effectiveness of atenolol compared to propranolol as first-line treatment of infantile haemangioma: A pilot study.

ABSTRACT: Propranolol is the first-line agent for the treatment of infantile haemangioma (IH). Due to its non-selective beta blockade respiratory adverse events are commonplace. Atenolol is a selective beta-1 antagonist and is a second line for patients with a significant respiratory history or those intolerant of propranolol. Previous studies suggest that the two treatments are equally efficacious; however; the narrow side effect profile and once-daily administration of atenolol makes it an attractive alternative. The aim of this study was to compare the cost-effectiveness of atenolol and propranolol in the treatment of IH. Over a two-year period, five patients with nine IH received the first-line treatment with atenolol. Nine individual lesions from six propranolol patients were matched to these l

SUBMITTER: Wilson S 

PROVIDER: S-EPMC9240956 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature